The company expects to launch more than 20 pivotal late-stage trials this year.

Pfizer Inc. (NYSE: PFE) is scheduled to provide its full-year 2026 financial guidance on Tuesday, with Bank of America Securities expecting the company's growth profile to closely resemble conditions ...

Pfizer may look cheap with a ~7% yield, but tight free cash flow, patent cliffs, and limited growth raise downside risk. Read ...

Yesterday, the Pharma giant Pfizer Inc. (PFE) took the unusual step of not only providing its full-year 2025 revenue and earnings numbers but also providing precise guidance for full-year 2026.